148 related articles for article (PubMed ID: 16480266)
1. Synthesis and structure-activity relationship studies of CD4 down-modulating cyclotriazadisulfonamide (CADA) analogues.
Bell TW; Anugu S; Bailey P; Catalano VJ; Dey K; Drew MG; Duffy NH; Jin Q; Samala MF; Sodoma A; Welch WH; Schols D; Vermeire K
J Med Chem; 2006 Feb; 49(4):1291-312. PubMed ID: 16480266
[TBL] [Abstract][Full Text] [Related]
2. Design and cellular kinetics of dansyl-labeled CADA derivatives with anti-HIV and CD4 receptor down-modulating activity.
Vermeire K; Lisco A; Grivel JC; Scarbrough E; Dey K; Duffy N; Margolis L; Bell TW; Schols D
Biochem Pharmacol; 2007 Aug; 74(4):566-78. PubMed ID: 17603023
[TBL] [Abstract][Full Text] [Related]
3. Unsymmetrical cyclotriazadisulfonamide (CADA) compounds as human CD4 receptor down-modulating agents.
Demillo VG; Goulinet-Mateo F; Kim J; Schols D; Vermeire K; Bell TW
J Med Chem; 2011 Aug; 54(16):5712-21. PubMed ID: 21800875
[TBL] [Abstract][Full Text] [Related]
4. Cyclotriazadisulfonamides: promising new CD4-targeted anti-HIV drugs.
Vermeire K; Schols D
J Antimicrob Chemother; 2005 Aug; 56(2):270-2. PubMed ID: 15980096
[TBL] [Abstract][Full Text] [Related]
5. CoMFA and CoMSIA studies on HIV-1 attachment inhibitors.
Lu P; Wei X; Zhang R
Eur J Med Chem; 2010 May; 45(5):1792-8. PubMed ID: 20149491
[TBL] [Abstract][Full Text] [Related]
6. 3D-QSAR models on clinically relevant K103N mutant HIV-1 reverse transcriptase obtained from two strategic considerations.
San Juan AA
Bioorg Med Chem Lett; 2008 Feb; 18(3):1181-94. PubMed ID: 18155520
[TBL] [Abstract][Full Text] [Related]
7. Syntheses and anti-HIV and human cluster of differentiation 4 (CD4) down-modulating potencies of pyridine-fused cyclotriazadisulfonamide (CADA) compounds.
Lumangtad LA; Claeys E; Hamal S; Intasiri A; Basrai C; Yen-Pon E; Beenfeldt D; Vermeire K; Bell TW
Bioorg Med Chem; 2020 Dec; 28(24):115816. PubMed ID: 33181479
[TBL] [Abstract][Full Text] [Related]
8. 3D QSAR CoMFA/CoMSIA, molecular docking and molecular dynamics studies of fullerene-based HIV-1 PR inhibitors.
Durdagi S; Mavromoustakos T; Papadopoulos MG
Bioorg Med Chem Lett; 2008 Dec; 18(23):6283-9. PubMed ID: 18951793
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and structure-activity relationships of azamacrocyclic C-X-C chemokine receptor 4 antagonists: analogues containing a single azamacrocyclic ring are potent inhibitors of T-cell tropic (X4) HIV-1 replication.
Bridger GJ; Skerlj RT; Hernandez-Abad PE; Bogucki DE; Wang Z; Zhou Y; Nan S; Boehringer EM; Wilson T; Crawford J; Metz M; Hatse S; Princen K; De Clercq E; Schols D
J Med Chem; 2010 Feb; 53(3):1250-60. PubMed ID: 20043638
[TBL] [Abstract][Full Text] [Related]
10. Docking and 3D-QSAR studies of BMS-806 analogs as HIV-1 gp120 entry inhibitors.
Teixeira C; Serradji N; Maurel F; Barbault F
Eur J Med Chem; 2009 Sep; 44(9):3524-32. PubMed ID: 19410340
[TBL] [Abstract][Full Text] [Related]
11. Improving potencies and properties of CD4 down-modulating CADA analogs.
Bell TW; Demillo VG; Schols D; Vermeire K
Expert Opin Drug Discov; 2012 Jan; 7(1):39-48. PubMed ID: 22468892
[TBL] [Abstract][Full Text] [Related]
12. Novel anti-HIV cyclotriazadisulfonamide derivatives as modeled by ligand- and receptor-based approaches.
Pinheiro JR; Bitencourt M; da Cunha EF; Ramalho TC; Freitas MP
Bioorg Med Chem; 2008 Feb; 16(4):1683-90. PubMed ID: 18053727
[TBL] [Abstract][Full Text] [Related]
13. CoMFA and CoMSIA studies on thiazolidin-4-one as anti-HIV-1 agents.
Murugesan V; Prabhakar YS; Katti SB
J Mol Graph Model; 2009 Feb; 27(6):735-43. PubMed ID: 19117780
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and three-dimensional quantitative structure-activity relationship analysis of H3 receptor antagonists containing a neutral heterocyclic polar group.
Rivara S; Mor M; Bordi F; Silva C; Zuliani V; Vacondio F; Morini G; Plazzi PV; Carrupt PA; Testa B
Drug Des Discov; 2003; 18(2-3):65-79. PubMed ID: 14675944
[TBL] [Abstract][Full Text] [Related]
15. 3D-QSAR CoMFA of a series of DABO derivatives as HIV-1 reverse transcriptase non-nucleoside inhibitors.
de Brito MA; Rodrigues CR; Cirino JJ; de Alencastro RB; Castro HC; Albuquerque MG
J Chem Inf Model; 2008 Aug; 48(8):1706-15. PubMed ID: 18671385
[TBL] [Abstract][Full Text] [Related]
16. Synthesis of amino derivatives of 10-(diphenylmethylene)-4-azatricyclo[5.2.1.0(2,6)]dec-8-ene-3,5-dione as potential psychotropic and/or anti HIV agents.
Kossakowski J; Wojciechowska A; KozioĊ AE
Acta Pol Pharm; 2006; 63(4):261-4. PubMed ID: 17203861
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and evaluation of 2-(2,6-dihalophenyl)-3-pyrimidinyl-1,3-thiazolidin-4-one analogues as anti-HIV-1 agents.
Rawal RK; Tripathi R; Katti SB; Pannecouque C; De Clercq E
Bioorg Med Chem; 2007 May; 15(9):3134-42. PubMed ID: 17349793
[TBL] [Abstract][Full Text] [Related]
18. Extension of the polyanionic cosalane pharmacophore as a strategy for increasing anti-HIV potency.
Cushman M; Insaf S; Paul G; Ruell JA; De Clercq E; Schols D; Pannecouque C; Witvrouw M; Schaeffer CA; Turpin JA; Williamson K; Rice WG
J Med Chem; 1999 May; 42(10):1767-77. PubMed ID: 10346929
[TBL] [Abstract][Full Text] [Related]
19. Non-nucleoside HIV-1 reverse-transcriptase inhibitors. Part 10. Synthesis and anti-HIV activity of 5-alkyl-6-(1-naphthylmethyl)pyrimidin-4(3H)-ones with a mono- or disubstituted 2-amino function as novel 'dihydro-alkoxy-benzyl-oxopyrimidine' (DABO) analogues.
Wang Y; Chen FE; Balzarini J; De Clercq E; Pannecouque C
Chem Biodivers; 2008 Jan; 5(1):168-76. PubMed ID: 18205120
[TBL] [Abstract][Full Text] [Related]
20. A quantitative structure-activity relationship and pharmacophore modeling investigation of aryl-X and heterocyclic bisphosphonates as bone resorption agents.
Kotsikorou E; Oldfield E
J Med Chem; 2003 Jul; 46(14):2932-44. PubMed ID: 12825934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
